Andy Studna

Standard for reaching patients shifts with influx of new technology in post-COVID world.

Looking Back at 2011–2014.

Hopeful new standard of care for advanced prostate cancer capitalizing on momentum.

Our editorial team presents the winners of our annual Emerging Pharma Leaders and their up-and-coming perspectives on a range of industry topics.

Script change from destined life in research to wild pace of biotech pays off.

A passion for building the business engine behind treatments for rare disease.